Acceleron Pharma (NASDAQ:XLRN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 208.82 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $27.94 million which missed the analyst consensus estimate of $33.44 million by 16.45 percent. This is a 29.71 percent decrease over sales of $39.75 million the same period last year.
Acceleron Pharma Q2 EPS $(1.05) Misses $(0.88) Estimate, Sales $27.94M Miss $33.44M Estimate
Acceleron Pharma (NASDAQ:XLRN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 208.82 percent decrease over losses of $(0.34) per share
